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Men with high-risk prostate cancer are at signiﬁcant risk of progressive, symptomatic disease leading to metastases or death from
prostate cancer. Surgery—speciﬁcally robotic-assisted laparoscopic prostatectomy (RALP)—is increasingly being considered as a
key component of a multimodal strategy to treat these patients. Herein, we review key technical considerations of performing
RALP with bilateral pelvic lymphadenectomy in men with high-risk disease. Recent literature supporting the increasing role of
surgery either alone or in combination with adjuvant therapies to treat men with high-risk prostate cancer is also reviewed.
1.Introduction
Men with localized high-risk prostate cancer represent a
group at signiﬁcant risk for metastases and death from
prostate cancer [1]. Historically, surgery was not the pre-
ferred option due to concerns about adequately assessing
subclinical metastatic disease, increased risk of positive
surgical margins, and a lack of randomized trials showing
a signiﬁcant clinical beneﬁt of radical prostatectomy over
radiotherapy [2, 3]. In the current era, where fewer men
present with bulky disease and most are considered high-risk
by Gleason grade alone, radical prostatectomy with pelvic
lymph node dissection (PLND) has become an important
and eﬀective treatment option for men with localized high-
risk disease [4]. In addition, with the diﬀusion of robotic-
assistedlaparoscopicprostatectomy(RALP)intotheurologic
community, this technique is being increasingly adopted to
treat high-risk patients [5–7]. Although there are several
technical considerations, in experienced hands RALP can
maintain oncological principles while minimizing patient
morbidity.HereinwereviewtheincreasingroleofRALPwith
pelvic lymphadenectomy either alone or in combination
with adjuvant therapies as a key component of a multimodal
treatment strategy for men with high-risk prostate cancer.
Ultimately, successful treatment approaches require careful
risk stratiﬁcation, delivery of quality treatment with curative
intent, consideration of multimodal approaches, and man-
agementofpatientexpectationswithinatherapeuticcontext.
2. Deﬁning High-Risk ProstateCancer
The characteristics of men diagnosed with prostate cancer
have changed dramatically over the last 2 decades largely as
a result of widespread serum PSA testing. Men with prostate
cancer now present with lower clinical stage and serum PSA,
and a greater proportion have low-risk features [8].
The characteristics of patients with high-risk prostate
cancer are also changing. Fewer patients are now diagnosed
with advanced prostate cancer than early in the PSA era.
Historically, nearly 40% of men presented with high-risk
disease based on clinical stage. Now only 15% of men
present with high-risk disease as a result of this stage
migration [4]. Nearly 60% of high-risk cases in the current
era are characterized as such based on Gleason grading
alone. Fundamental work by Pound and colleagues helped to
establish the natural history of prostate cancer in surgically2 ISRN Urology
treated patients [9]. At a median of 8 years they identiﬁed
biochemical recurrence in 15% and found metastatic disease
developing in 34% of this group. In survival analysis, time
to biochemical progression (P<. 001), Gleason score (P<
.001), and PSA doubling time (P<. 001) were predictive of
the probability and time to the development of metastatic
disease.
D’Amico et al. continued this work by reﬁning criteria
to identify those at high risk of progression. They identiﬁed
clinicopathologicalfeaturesthatpredictedadverseoutcomes,
including development of metastatic disease and death from
prostate cancer, and in doing so, helped to establish the most
commonly accepted deﬁnition [10]. They identiﬁed PSA >
20ng/mL,Gleasongrade8–10,and>cT2cﬁndingsondigital
rectalexaminationasimportantfactorstoidentifymenatthe
highest risk of progression.
3. Optimal Treatment
There is no consensus on the optimal treatment of high-risk
nonmetastatic prostate cancer. Historically, prostatectomy
for Gleason 8–10 disease was not considered curative, and
many practitioners directed patients towards external beam
radiotherapy or primary hormonal treatment. Cooperberg
et al. identiﬁed signiﬁcant diﬀerences in practice patterns
among urologists for treatment of men with high-risk
disease. In their study spanning from1998 to 2007, men with
high-risk disease were oﬀered primary androgen deprivation
therapy or external beam radiotherapy over radical prosta-
tectomy [11]. Other studies show that men with high-grade
prostate cancer may be cured with surgery either alone or
in combination with radiotherapy ± androgen deprivation
therapy [12–15]. The Shared Equal Access Regional Cancer
Hospital (SEARCH) group has also shown that not all men
with biopsy Gleason 7–10 disease have poor outcomes [16].
In this study, men with pathologic Gleason 4+3 experienced
similarratesofbiochemicalrecurrenceasthosewithGleason
8–10 cancer. Based on these ﬁndings radical prostatectomy
hasbecomeakeycomponentofmultimodaltherapyformen
with high-risk disease [17].
4. Staging and Risk Assessment of High-Grade
ProstateCancer
4.1. Clinical Features: Gleason Score, PSA, and DRE. Not all
high-risk prostate cancers are deﬁned by a single parameter,
but Gleason score, PSA, PSA kinetics, and digital rectal
exam used in combination are useful in assigning risk and
clinically staging patients. Gleason biopsy grading is one of
the strongest predictors of biochemical recurrence (BCR)
as well as disease-speciﬁc and overall survival [9, 10, 18].
In general, the more granular the pathologic assessment of
biopsy material, the better risk assessment can be made.
That is, the number, percentage, or total length of cancer
detected per number of cores or amount of tissue sampled
provides important diagnostic information to the clinician
for risk stratiﬁcation. These details are also increasingly
being incorporated into risk stratiﬁcation models such as the
Kattan, CPDR, and CAPRA nomograms [19, 20].
In the current era few patients are characterized as high
risk by PSA alone. Although elevated PSA levels may be due
to cancer, benign prostatic enlargement and inﬂammatory
or infections conditions may also increase concentrations.
In these patients, evaluation of metastatic disease takes on
greater importance and may include bone scan and com-
puted tomography of the abdomen and pelvis. Interesting
work in the area of red bone marrow axial skeleton magnetic
resonance imaging has also demonstrated improved sensi-
tivity and speciﬁcity at detecting metastasis from prostate
cancer [21, 22].
Clinically advanced disease with digital exam ﬁndings of
cT3orgreaterarelesscommonnowthaninthepast.Inthese
patients advanced imaging techniques including endorectal
coil MRI or detailed ultrasound examinations of the prostate
with or without power Doppler may help better deﬁne the
lesion [23]. Identiﬁcation of bladder neck or seminal vesicle
invasion can be used to help surgical planning.
4.2. Staging and Treatment Considerations. Age, comorbidi-
ties,andlifeexpectancyshouldbeconsideredbeforedeciding
on a treatment strategy, as not all options may be reasonable
for every patient. Surgery oﬀers patients the potential of
long-term cure with the distinct advantage of local disease
control.Prostatectomyhasbeenshowntopreventlocalcom-
plications including recurrent hematuria, urinary retention,
pain and hydronephrosis. Careful discussion of expectations
and outcomes is necessary before considering local therapy
with curative intent. Although many patients with high-risk
prostate cancer expect cure, prostatectomy can only achieve
this for some 40%–60% of patients. Many will need to
consider surgery as only one arm in a multimodal approach.
5.Technique of Robotic-Assisted Laparoscopic
Prostatectomy in High-Risk ProstateCancer
5.1. Approach and Access. The majority of RALP procedures
are performed using the transperitoneal approach. In addi-
tion to ease of access, this technique oﬀe r sa d v a n t a g e so fa
large working space with better proximal and medial access
to lymph nodes over a retroperitoneal approach. Several
technical considerations may facilitate RALP in patients with
high-risk disease (Table 1).
The robot is docked after establishing pneumoperi-
toneum and placing ports. Typical port placement includes
an 8mm robotic port 15cm lateral to the umbilicus on
the right; a single 12mm assist port 6 cm lateral to the
umbilicus on the right; two left-sided 8mm robotic ports,
one 10cm lateral to the umbilicus, and one 3cm medial
to the anterosuperior iliac spine. Close inspection of the
abdomen will identify any initial access injuries and bowel
adhesions that must be divided before proceeding. We favor
a posterior approach with initial reﬂection of the sigmoid
colon to gain a better view of the pelvis.
Next we place gentle cranial retraction on the rectum
and make a transverse peritoneotomy between the bladder
and the rectum. After transaction of each vas deferens,ISRN Urology 3
Table 1: Technical considerations for RALP with extended pelvic lymph node dissection in high-risk patients.
Division of lateral physiologic adhesions of rectum and sigmoid to left pelvic side wall, facilitating elevation of bowel out of pelvis.
Posterior approach begins with perneotomy and dissection of seminal vesicles under direct vision.
Incise Denonvillier’s fascia under elevated seminal vesicles and establish safe plane between prostate and rectum.
Mobilize bladder and incise peritoneum to level of vas deferens bilaterally to facilitate extended pelvic lymph node dissection.
Consider extrafascial or modiﬁed nerve sparing with medial endopelvic fascia incision to balance oncologic control with quality of life
outcomes.
Err towards bladder while opening anterior bladder neck.
Meticulous circumferential dissection of the prostate apex is necessary to avoid positive surgical margins.
Identify ureter crossing over common iliac artery and incise peritoneum to begin extended pelvic lymph node dissection.
Consider placement of metal clips at prostate pedicles and during lymphadenectomy to facilitate targeting of postoperative radiotherapy.
the seminal vesicles are dissected circumferentially and 5-
mm polymer clips are placed on the small blood vessels
that emanate from their tips. High-risk prostate cancer
may be associated with ﬁrm seminal vesicle tissue that is
characteristicofinvasionandrequirescarefulroboticmanip-
ulationtoensurecompleteremoval.Whileliftingtheseminal
vesicles, a transverse incision is made in Denonvillier’s fascia
to establish the dissection plane between the rectum and
prostate. Establishing this plane may be diﬃcult in case of
advanced disease, prior treatment with androgen ablation or
radiotherapy, and in the setting of multiple prior biopsies or
transurethral resection of the prostate; however, this is not
universal.
5.2. Endopelvic Dissection. The anterior dissection begins by
opening the space of Retzius by dividing from one medial
umbilical ligament to the other and the urachus in the
midline. The peritoneum is opened widely down to where
the vas deferens crosses the external iliac vein. Firm cranial
retractiononthebladderfacilitatesevaluationoftheanterior
surface of the prostate. High release of endopelvic fascia
is initiated with sharp dissection, and the dorsal venous
complexiscontrolledwithanendo-GIAstaplerusingagreen
load.
5.3. Nerve Sparing. The degree of nerve sparing should
be determined by exam, clinical risk stratiﬁcation, and
preoperative imaging if available. Several authors have
demonstrated nerve-sparing RALP can be safely performed
in patients with preoperatively high-risk prostate cancer
[5]. In a recent report, Shikanov and colleagues evaluated
potency and positive surgical margins after intrafascial or
extrafascial nerve sparing [24] .T h e yf o u n dat r e n dt o w a r d
lowerpositivesurgicalmarginsinthepT3group(51%versus
28%; P = 0.08). Further, they noted signiﬁcantly fewer
mid- and posterolateral positive margins in the extrafascial
group 11% versus 37% and 11% versus 29%, respectively
(P<0.001), at the expense of slightly worse potency at 12
months postoperatively.
5.4. Bladder Neck Dissection. The anterior bladder neck is
then incised with electrocautery. With the Foley catheter
now lifted, the prostate is circumferentially dissected from
the base of the prostate. After opening clearly entering the
retrovesical space the previously dissected seminal vesicles
may be elevated to assist with pedicle ligation. Urologists
should avoid the natural tendency to advance towards the
prostate and use a perpendicular place of dissection between
the bladder neck and prostate base to avoid a positive
surgical margin. Frozen section analysis may be useful in
selected cases [36, 37]. Visual clues to decrease the risk
of posterior-lateral surgical margins include appreciation of
periprostatic (lateral prostatic) fascial compartments; color
and texture of the tissue; periprostatic veins as a landmark
for athermal dissection; signs of inﬂammation; a freely
separating bloodless plane showing loose shiny areolar tissue
[38].
Athermic technique with use of surgical clips may be
used to complete pedicle ligation and mobilization of the
prostate base. Meticulous circumferential dissection of the
prostate apex is necessary to avoid positive surgical mar-
gins near the urethra. The vesicoureteral anastamosis is
completed after pelvic lymphadenectomy using a running
3–0 double-armed, absorbable suture with care taken to
avoid inclusion of rhabdosphincter ﬁbers in the anastamosis.
The tendency to perform a wide dissection here is also a
potential for complications. Rectal injury is more common
in the setting of retrograde dissection with an inadequately
dissected posterior plane. A wide dissection also threatens
urinary continence by sacriﬁcing both urethral length and
rhabdosphincter integrity.
6. Review of Robotic AssistedLaparoscopic
Prostatectomy Series for High-Risk Disease
The proportion of men undergoing robotic prostatectomy
diagnosed with high-risk disease is increasing. This trend
has been noticed at large academic centers and will likely to
continue as more low-risk patients select active surveillance
[39]. Several RALP series focused on high-risk prostate
cancer have been published (Table 2). Within this group
there is signiﬁcant variation in the deﬁnition of high risk,
which makes comparison across studies challenging.
Locallyadvancedprostatecancercharacterizedbyclinical
T3 or greater disease may be among the most diﬃcult
challenges for RALP. Bulky disease and increased risk of4 ISRN Urology
Table 2: Published robotic assisted laparoscopic prostatectomy series for high risk disease.
Series Patients Risk group Nodes + (%) Seminal vesicle
invasion (%)
Positive margin
(%)
Biochemical
recurrence
(%)/median
followup
Adjuvant
therapy
(%)
Lavery et al. 2010 [5] 123 D’Amico high risk∗ 2.4 32 31 26 26
Ham et al. [6] 121 ≥cT3a locally advanced 24 — 48.8 — —
Shikanov et al. [7] 70 Biopsy Gleason 8–10 12.9 14 24.2 13/9.6mo. 13
Casey et al. [25]3 5 Final ≥pT3, with 29%
D’Amico high risk∗ 19 37 20 28.6/13mo. 37
Jayram et al. [26] 148 D’Amico high risk∗ 12.3 20.5 21.3/24mo. 23.3
Yee et al. [27] 62 D’Amico high risk∗ — — 22.6 —
Badani et al. [28] 177 D’Amico high risk∗ —— 3 5 † 47.2/22mo.‡
∗D’Amico’s criteria for high-risk prostate cancer were utilized: prostate-speciﬁc antigen ≥20ng/mL, clinical stage ≥T2c, or preoperative Gleason grade ≥8.
†Assessed in patients with pathologic T3 disease.
‡Assessed in patients with pathologic Gleason grade ≥8.
bladder neck involvement or seminal vesicle invasion can
make robotic dissection diﬃcult. Casey et al. demonstrated
excellent short-term results in 35 patients with pathologic
T3 disease who underwent RALP. At a median of 13 months
followup, they noted 28.6% with biochemical recurrence,
37% with seminal vesicle invasion, and 20% with positive
margins.
RALP has also been studied in other high-risk, organ-
conﬁned prostate cancer groups. Men with one or more
other high-risk features including PSA ≥ 20ng/mL and
Gleason score 8–10 are included here. Surgical skill and
technicalexpertisedriveoutcomesparticularlyinthesecases.
Inadvertent capsular incisions that create positive margins,
excessive neurovascular bundle resection, and poor man-
agement of urethral length are among the most important
potentially avoidable surgical errors.
7. PelvicLymphadenectomy
The role and extent of pelvic lymphadenectomy at the time
ofradicalprostatectomyhaveevolvedinrecenthistory.There
is ongoing discussion in the literature regarding who should
undergo pelvic lymph node dissection (PLND), the extent
of the dissection that should be performed and whether
PLND provides therapeutic beneﬁt in addition to staging
information. In patients with high-risk prostate cancer we
perform a bilateral extended pelvic lymph node dissection
before completion of the vesicoureteral anastamosis [40].
Investigators have clearly shown that the lymphatic drainage
of the prostate is not limited to the obturator and external
iliac lymph nodes, and thus a PLND limited to these
regions does not address all the potential draining sites. An
extended pelvic lymph node dissection (EPLND), including
the internal iliac lymph nodes along with external iliac and
obturator nodes, more accurately reﬂects the true lymphatic
drainage of the prostate, increases nodal yield, and improves
detection of metastatic lymph nodes.
An emerging body of evidence supports completion
prostatectomy in the setting of positive lymph nodes to pro-
vide local control. In a carefully matched group of patients
with lymph node metastasis at the Mayo Clinic, the 10-year
probability of overall survival was 66% for those undergoing
prostatectomy with subsequent androgen deprivation ther-
apy and 28% for those treated with androgen deprivation
alone [41]. In a study from Germany, Engel et al. published
results also supporting a survival advantage in those treated
with prostatectomy in the setting of positive pelvic lymph
nodes [42].
7.1. Robotic Extended Pelvic Lymph Node Technique. Robotic
EPLNDbeginsbycarefullyincisingtheperitoneumoverlying
the common iliac artery, taking care to remain lateral to
the ureter. Medial retraction of the bladder can facilitate
identiﬁcation of triangular apex of lymphatic tissue that sits
at the bifurcation of the common iliac artery. The dissection
of lymphatic tissue is antegrade down along the hypogastric
artery to the origin of the medial umbilical ligament. These
internal iliac (hypogastric) nodes are omitted in the standard
PLND. Next we dissect the lymphatic tissue along the
external iliac artery down to the node of Cloquet. The
crossing circumﬂex vein can often be preserved with careful
dissection. Retrograde dissection along the external iliac vein
and sweeping maneuvers towards the elevated packet facil-
itate separation of the obturator nodes. Medial and lateral
nodaltissuemaybesplitovertheobturatornervetofacilitate
the dissection. External iliac, obturator, and internal iliac
nodes can often be removed en block. Surgeons have used
mono or bipolar electrocautery, polymer clips, or metal clips
to ligate vessels and lymphatics. All appear to have similar
complication rates. Select placement of metal clips at the
bladder pedicles and in the area of lymphadenectomy may
facilitate postoperative radiotherapy. A committed surgical
approach that respects anatomic pitfalls can yield excellent
nodal counts while minimizing complications.
8. Review of Robotic-Assisted Extended
PelvicLymph Node Dissection
Pelvic lymphadenectomy during RALP is technically feasible
and appears to have minimal morbidity as well as highISRN Urology 5
Table 3: Summary of robotic extended and standard pelvic lymph node dissection series for RALP.
Robotic series Patients Mean lymph nodes
retrieved (range)
Patients with positive
lymph nodes (%)
Clinical lymphocele
(%)
Extended
Feicke et al. [29]9 9 1 9 1 6 4
Yee et al. [30] 32 18 12.5 0
Yates et al. [31]6 2 3 . 3 3 . 2 —
Truesdale et al. [32]9 9 6 1 —
Standard
Atug et al. [33] 40 14.1 5 0
Polcari et al. [34]6 0 8 . 2 3 . 3 3
Zorn et al. [35] 296 12.5 7.7 2
lymph node yield which may improve pathologic staging
and provide therapeutic beneﬁt. Table 3 summarizes current
extended and standard lymphadenectomy robotic series,
including all risk categories. Several studies note that men
with limited micrometastatic disease may be cured by PLND
at the time of radical prostatectomy. In one series, Yee et
al. reported on the feasibility of robotic assisted extended
pelvic lymph node dissection in 32 men [30]. In their study
EPLND included obturator, internal iliac, external iliac, and
common iliac nodes to bifurcation of aorta. Positive lymph
nodes were noted in 12.5% after a median of 18 nodes
removed per patient, and there were no lymphoceles or
serious complications. A report by Feike et al. identiﬁed
lymph node metastases in 16% of patients with a mean 19.4
nodes resected. Twenty-ﬁve percent of positive nodes were
detected in the internal iliac distribution.
9. IntegratingAdditional Therapy
9.1. Adjuvant and Salvage Radiotherapy. Three randomized
controlled trials are available that have addressed the timing
or need for adjuvant external beam radiotherapy after
prostatectomy: the German Cancer Society trial, the EORTC
22911, and the SWOG 8794 trial. All have supported
adjuvant external beam radiotherapy after prostatectomy
for advanced localized prostate cancer by demonstrating
improved biochemical recurrence-free survival rates and
improved metastasis-free survival in the SWOG trial. Those
with positive surgical margins and locally advanced disease
are most likely beneﬁt from adjuvant radiotherapy. Adjuvant
radiotherapy is generally administered between 3 and 6
months postoperatively. It is unclear what diﬀerences exist
between early salvage radiotherapy and adjuvant radiother-
apy in the era of superselective PSA. Generally patients
experience only modest toxicity.
10. SalvageRALP in Men with
High-RiskFeatures
Recurrence in high-risk disease results from either inade-
quate primary treatment or interval development metastatic
disease. Salvage prostatectomy is generally reserved for men
with evidence of local disease. Careful restaging and meta-
static workup with repeat prostate biopsy, abdomen-pelvic
imaging, and consideration of bone scan or axial skeleton
bone marrow MRI are requisite. A thorough discussion with
patients is needed with particular emphasis on postoperative
functionaloutcomes,includingcontinenceanderectilefunc-
tion.
11. Conclusion
RALP with pelvic lymphadenectomy either alone or in
combination with adjuvant therapy is an important treat-
ment option for men with high-risk prostate cancer. RALP
can provide eﬀective management of locally advanced and
high-risk prostate cancer while achieving excellent oncolog-
ical outcomes. Surgical experience and close attention to
preservation of anatomic structures may improve outcomes.
Extended pelvic lymph node dissection plays an important
therapeutic and staging role in management of high-risk
prostate cancer.
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